NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

Search

Coloplast A-S (Class B)

Cerrado

602 -0.23

Resumen

Variación precio

24h

Actual

Mínimo

595

Máximo

610

Métricas clave

By Trading Economics

Ingresos

-132M

912M

Ventas

-96M

6.9B

P/B

Media del Sector

30.208

50.291

BPA

4.34

Rentabilidad por dividendo

3.61

Margen de beneficios

13.16

Empleados

16,741

EBITDA

-42M

2.2B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+11.86% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.61%

2.40%

Próximas Ganancias

19 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-19B

138B

Apertura anterior

602.23

Cierre anterior

602

Coloplast A-S (Class B) Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 jun 2025, 23:49 UTC

Ganancias

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 jun 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 jun 2025, 21:30 UTC

Ganancias

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Ganancias

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 jun 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 jun 2025, 23:39 UTC

Charlas de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 jun 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 jun 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 jun 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 jun 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 jun 2025, 23:19 UTC

Adquisiciones, fusiones, absorciones

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 jun 2025, 22:06 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:15 UTC

Ganancias

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 jun 2025, 21:07 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 jun 2025, 21:06 UTC

Charlas de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 20:52 UTC

Ganancias

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 jun 2025, 20:51 UTC

Ganancias

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Coloplast A-S (Class B) previsión

Precio Objetivo

By TipRanks

11.86% repunte

Estimación a 12 Meses

Media 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Coloplast A-S (Class B) Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

2

Comprar

4

Mantener

2

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.